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Background: DNA methylation at specific CpG sites within gene promoter regions is known to regulate
transcriptional activity in vitro. In human adipose tissue, basal transcription of the aromatase (CYP19A1) gene is
driven primarily by the I.4 promoter however the role of DNA methylation in regulating expression in ex vivo
mature adipocytes is unknown. This observational study reports the correlation of DNA methylation within the I.4
promoter region of human mature subcutaneous and omental adipocytes with aromatase expression and body
composition measures.
Methods: Omental and subcutaneous adipose tissue were collected from 25 obese subjects undergoing bariatric
surgery and the mature adipocyte fraction purified. DNA methylation status of 5 CpG sites within a 550 base pair
region encompassing the transcription start site (TSS) of promoter I.4 was determined using pyrosequencing.
Relative aromatase and I.4 promoter specific mRNA expression was determined by qRT-PCR and whole body DXA
performed in 25 participants.
Results: Site-specific DNA methylation varied from 21 ± 10% to 81 ± 11%. In omental adipocytes percentage
methylation at the I.4.1 and I.4.2 CpG sites, but not other nearby sites, was negatively correlated with relative
aromatase mRNA expression (R = - 0.52, P = 0.017 and R = - 0.52, P = 0.015). In contrast subcutaneous adipocytes
percentage DNA methylation at the I.4.3 and I.4.5 sites were positively correlated with relative aromatase mRNA
expression (R = 0.47, P = 0.022 and R = 0.55, P = 0.004). In a small subset of patients DNA methylation at the I.4.5 site
was also positively correlated with whole body lean mass, bone mineral content and density.
Conclusions: In conclusion in mature adipocytes, the primary source of estradiol after menopause, increasing DNA
methylation was correlated with aromatase mRNA expression and thus estradiol biosynthesis. These findings
support a tissue-specific epigenetic regulation of the basal promoter activity in mature adipocytes; the mechanisms
influencing this regulation and its physiological role remain to be elucidated.
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Estrogen biosynthesis is catalysed by the aromatase en-
zyme which converts androstendione to estrone and tes-
tosterone to estradiol [1,2]. Aromatase is a cytochrome
P450 enzyme produced by the human CYP19A1 gene
located on chromosome 15q21.2 [3]. The gene com-
prises of an upstream regulatory region spanning ap-
proximately 93 kb and a downstream coding region
consisting of 9 coding exons, II-X, spanning 30 kb [4].
Aromatase expression has been detected in the ovary,
placenta, breast, testes, adipose tissue, bone, peripheral
blood leucocytes and brain [4,5]. However adipose tissue
is the primary source of estrogen in women after meno-
pause and is important in maintaining bone remodelling
and regulating adipose mass. Tissue specific aromatase
gene expression is determined in part by tissue-specific
promoters in the regulatory regions upstream of the un-
translated first exon which gives rise to transcripts with
unique 5′ non-coding termini [6-8].
In human adipose tissue, basal transcription of aroma-
tase has been demonstrated to be driven primarily
through the I.4 promoter [7,9-11] with a 500 bp region
of the aromatase I.4 promoter located 330 bp upstream
to 170 bp downstream of the transcription start site
(TSS) been shown to regulate glucocorticoid responsive-
ness [9]. DNA methylation is an epigenetic mark which
involves the addition of a methyl group to the fifth car-
bon of the cytosine ring, forming 5-methylcytosine. The
reaction is catalysed by DNA methyltransferases and pri-
marily occurs in a 5′ CpG dinucleotide context [12].
Typically DNA methylation is associated with repressing
gene expression [13] and activation of genes has been
attributed to the demethylation of critical CpG loci both
in vitro and in vivo [12,14-17] however intragenic DNA
methylation paradoxically has been shown to be associ-
ated with increased gene expression [18-20]. DNA
methylation has also been suggested to regulate placen-
tal [21] and ovarian [22] aromatase expression in cattle,
while a recent in vitro study [11] suggested an inverse
association between DNA methylation in the aromatase
I.4 promoter region and aromatase gene expression in
human breast adipose fibroblasts and breast cell lines
however the relationship between DNA methylation and
other cell types has not been investigated.
In men and after menopause in women pre-adipocytes
and mature adipocytes are considered the primary
source of circulating levels of estradiol after menopause
[23]. Endogenous production of estradiol and therefore
its regulation in adipose tissue has important clinical im-
plications for a range of diseases including breast cancer
[24], Alzheimer’s disease [25] and fracture [26]. Previous
studies by our group and others have investigated the as-
sociation of genetic polymorphisms within the aroma-
tase gene with estradiol levels, bone mineral density, andfracture risk [26-31], however little is known regarding
the role of epigenetic regulation of the aromatase gene.
We therefore used human ex vivo mature adipocytes
from the subcutaneous and omental sites to test the as-




Patients undergoing bariatric surgery at Sir Charles
Gairdner Hospital were invited to participate in the
study. Twenty five participants were recruited for the
study and adipose tissue samples collected at surgery.
Each participant gave written informed consent and the
study was approved by the institutional ethics committee
of Sir Charles Gairdner Hospital.
Body composition and bone mineral density
Whole body dual x-ray absorptiometry (DXA) was
performed in 10 participants during a clinic visit post-
surgery and headless bone area, mineral content and
density as well as whole body bone free lean mass and
fat mass on a fan-beam densitometer (Hologic Acclaim
4500A; Hologic Corp, Waltham, Mass) were measured.
Adipocyte isolation
Omental and subcutaneous adipose tissue was taken
during bariatric surgery. Adipose tissue was rapidly
processed after surgery using a modified protocol [32].
Briefly, connective tissue, blood vessels and fibrous ma-
terials were removed from the adipose tissue samples.
The tissue were then homogenised and incubated in col-
lagenase digest solution (25 mM HEPES, 5 mM glucose,
120 mM NaCl, 50 mM KCl, 7.5 mM CaCl2, 3 mg/ml
Type II Collagenase, Sigma) with a ratio of 4:1 at 37°C
in a 180 rpm shaker for 1.5 hours. The digest was then
passed through a 500 μm nylon mesh and spun at 700 g
for 10 min. After gentle agitation of the culture for 30
seconds the floating layer of cells that resurfaced (ma-
ture adipocytes) were then collected and the procedure
repeated twice more. This method of isolating adipo-
cytes has been shown to result in ~3-4 contaminating
pre-adipocytes per 1,000 mature adipocytes, as described
by others [33]. Cells were stored at −80°C in RNAlater
prior to extraction. RNA samples were extracted using
the AllPrep DNA/RNA and protein kit (Qiagen, VIC,
Australia) according to the manufacturer’s instructions.
RNA concentrations were then determined by spectro-
photometry (ND-1000, Nanodrop Technologies, USA)
with a 260/280 of 1.8 or greater. Where available mature
adipocytes from 36 of the original 50 samples were re-
extracted using the AllPrep Mini Kit (QIAGEN) for PI.3
and PI.4 transcript expression analysis.
Table 1 Primer sequences for primers used in the PCR
and pyrosequencing reactions
Primer name Sequence (5′ to 3′)
I.4.1, I.4.2a I.4a PCR F GGAATGGTGAGAGTTTGGTTAATG
I.4a PCR R *CAAAAAACACCCTAAAATATAACCTACAA
I.4a Seq.b GTAAAGTGTTTGTTTTTTTATAGT
I.4.3, I.4.4a I.4c PCR F GGAATGGTGAGAGTTTGGTTAATG
I.4c PCR R *CAAAAAACACCCTAAAATATAACCTACAA
I.4c Seq.b CTACAATAAAAACACATTTCTT
I.4.5 I.4b PCR F *AGGAGATTTTTGATTTATGTGGGGTTATG
I.4b PCR R ACTCAAACTCCAAAAACTTACCTAAT
I.4b Seq.b CCCATCACATCACTC
aEncompasses two CpG sites upstream of the promoter. bSequencing primer.
*Biotinylated at 5′ end and HPLC purified to enable capture of the PCR
products by the PyroMark vacuum station filter probes.
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Pyrosequencing assays were designed using the Pyro-
Mark assay design software (version 2.0, QIAGEN). The
most recent version of the genomic DNA sequence was
imported into the assay design software (accession num-
ber L21982). The region of interest for this study was
identified as being 350 bp upstream of the transcription
start site to 200 bp downstream as this region has previ-
ously been identified to be responsible for glucocorticoid
stimulated aromatase gene expression in primary hepa-
tocytes and adipose derived stromal cells [9]. This re-
gion encompasses a glucocorticoid response element
from −133/119 bp and an SP1 binding site +151/158
responsible for glucocorticoid responsiveness [9] as well
as a RUNX2 binding site from −231/204 bp [34] and a
interferon-gamma activation site element from −282/272
bp [35] which are involved in activation of I.4 promoter
specific transcription (Figure 1). Primers were designed
for the 5 CpG sites within this region. In silico bisulfite
conversion was performed by converting all CG’s in the
gDNA sequence to YG’s and any remaining C’s to T’s.
Sites I.4.1 (−350 bp), I.4.2 (−316 bp), I.4.3 (−174 bp),
I.4.4 (−85 bp) and I.4.5 (+152 bp) correspond to CpG
sites 4, 5, 6, 7 and 8 respectively, described by Knower
et al. [11]. The primer sets which resulted in the highest
primer score based on the predictive likelihood of
primers forming duplexes and hairpins, mispriming or
the amplicon looping for sites 1, 2 and 5 were selected
(Table 1).
Pyrosequencing assay
Unmethylated cytosines were converted to uracil using
the EpiTect bisulfite kit (QIAGEN) according to the
manufacturer’s instructions. Bisulfite converted DNA was
determined by spectrophotometry (ND-1000, Nanodrop
Technologies, USA) and 40 ng was amplified using the
PyroMark PCR kit (QIAGEN) as per the manufacturer’sFigure 1 Location of the 5 CpG sites analysed within the I.4 promote
sites analysed relative to the transcription start site (TSS, +1) of I.4, sites 1- 5
circles (5, 14, 37). GAS, interferon γ activation site; GRE, glucocorticoid respoinstructions. Cycling conditions were as follows: 95°C for
15 min, 45 cycles of 94°C for 30 s, 56°C for 30 s and 72°C
for 30 s, followed by a final extension step at 72°C for 10
mins. 2 μl of well-mixed streptavidin sepharose high per-
formance slurry (GE Healthcare) and 40 μl of binding buf-
fer (QIAGEN) was diluted in 18 μl of water in each well,
followed by addition of 20 μl of PCR product generated
previously. The mixture was vortexed for 5 mins at 1,400
rpm and the 24-well plate containing the PCR product-
streptavidin mix was placed on the PyroMark Vacuum
station. With the vacuum on, the filter probes were placed
in sterile water for 10 s and inserted into the 24-well plate
containing the PCR product-streptavidin mix to capture
the double stranded PCR (dsPCR) product. The dsPCR
product was washed in 70% ethanol solution for 5 s and
then denaturation solution (QIAGEN) for 5 s. The single
stranded biotinylated template was washed in 1 × wash
buffer (QIAGEN) for 10 s and released by agitation. The
template DNA was annealed to the sequencing primer by
incubating the PyroMark Q24 plate at 80°C for 2 min. Ther region of the aromatase gene. Numbers indicate positions of CpG
n refer to I.4.1 – 5 respectively. Cis-acting elements are shown in
nse element; Runx2, Runt-related transcription factor 2.
Figure 2 Mean ± SEM of percentage DNA methylation at the 5
CpG sites within the I.4 promoter of subcutaneous adipocytes
compared to omental adipocytes. *** represents significantly
different from omental adipocytes P < 0.001.
Lewis et al. BMC Medical Genetics 2013, 14:87 Page 4 of 8
http://www.biomedcentral.com/1471-2350/14/87PyroMark Q24 cartridge was loaded with PyroGold Q24
reagents, according to pre-run information (PyroMark
Q24 software). Each run contained at least 1 internal
bisulfite conversion control whereby C bases not followed
by a G (typically not methylated) should be fully converted
to T after bisulfite treatment. All runs also included a no
template control. The proportion of DNA molecules
methylated at each CpG site was automatically calculated
by the PyroMark Q24 software and expressed as a per-
centage. As previously reported, the quantitative reprodu-
cibility of technical replicates amplified by the same PCR
is approximately 2% and variation induced by different
bisulfite treatments and/or separate PCR amplifications is
approximately 5% [36].
Relative aromatase mRNA expression
mRNA from the adipocytes was reverse transcribed using
the QuantiTect reverse transcriptase kit (QIAGEN), ac-
cording to manufacturer’s instructions, including a gen-
omic DNA elimination step and adding the maximum
amount of template mRNA possible. Total aromatase
mRNA expression was then determined using the Quanti
Fast SYBR green PCR kit (QIAGEN) and QuantiTect
primer assay (Hs_CYP19A1_2_SG; QIAGEN) according
to the manufacturer’s instructions, in an iQ5 real time
PCR thermal cycler (BioRad). Briefly, each reaction
consisted of 1× QuantiFast Master mix, 1× QuantiTect
primer assay, 4 μl of cDNA previously diluted 1:2 with
RNase-free H2O and made up to 15 μl with RNase-free
H2O. The primers amplified an 82 bp region of aromatase
(accession numbers: NM_000103, NM_031226). Aroma-
tase mRNA expression was normalised to 18S rRNA gene
expression, which was determined using the same condi-
tions as above but with a different QuantiTect Primer
Assay (Hs_RRNA18S_1_SG; QIAGEN). Where available
(n = 36) excess adipocytes were stored in RNAlater®
(QIAGEN) were re-extracted and relative promoter ex-
pression was calculated using RT-PCR using I.4 and I.3
promoter specific forward primers with a common reverse
primers as described by Demura et al. [37].
Statistical analysis
Differences between groups were investigated using in-
dependent samples T-Tests and tissue depots by paired
sample T-Tests. Spearman’s Rank correlation coefficient
(R) was used to investigate the relationships between
percentage DNA methylation and relative aromatase
mRNA expression, age, body mass index, lean mass, fat
mass and bone phenotypes. All correlations observed
were tested with and without outliers and with and with-
out men to account for potential gender differences.
P values < 0.05 were considered statistically significant.
Results were analysed using SPSS (PASW Statistics, ver-
sion 18). Results are given as mean ± standard deviation.Results
Cohort characteristics
The subjects consisted of 22 women and 3 men under-
going bariatric surgery. The mean age was 46.1 ± 13.8
years, height 166.7 ± 8.8 cm, weight 121.3 ± 24.2 kg and
body mass index (BMI) 43.4 ± 8.1 kg/m2.
DNA methylation of CpG sites within the regulatory
region of the I.4 promoter
The four CpG sites upstream of the TSS identified by the
PyroMark assay design software were I.4.1 and I.4.2, I.4.3
and I.4.4 while the CpG site I.4.5 was located downstream
of the TSS (Figure 1). The percentage DNA methylation of
the mature adipocytes from the omental and subcutane-
ous depots for the 5 CpG sites studied is shown in
Figure 2. Three of the upstream CpG sites; (I.4.2 – I.4.4)
had significantly different percentage DNA methylation
between omental and subcutaneous adipocytes.
Site specific methylation and relative total mRNA
expression
Omental adipocytes
Total relative aromatase expression in omental adipo-
cytes was 0.42 ± 0.15 in omental adipocytes. In omental
adipocytes percentage DNA methylation at CpG sites
I.4.1 and I.4.2 was negatively correlated with relative
total aromatase mRNA expression (R = −0.516, P = 0.017
and R = −0.522, P = 0.015 respectively). DNA methyla-
tion was not significantly correlated with total aromatase
expression at sites I.4.3 (R = −0.203, P = 0.391), I.4.4
(R = −0.131, P = 0.582) or I.4.5 (R = −0.263, P = 0.237).
The association between DNA methylation and total
aromatase expression became non-significant at the I.4.1
site after the exclusion of men from the analysis
(R = −0.462, P = 0.054). Similarly the correlation between
the I.4 promoter specific mRNA expression and 1.4.1
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(R = −0.357, p = 0.199 and −0.262, P = −0.311).Subcutaneous adipocytes
Total relative aromatase expression in subcutaneous
adipocytes was 0.42 ± 0.15in subcutaneous adipocytes. In
subcutaneous adipocytes percentage DNA methylation
at the I.4.3 and I.4.5 CpG sites were positively correlated
with relative total aromatase mRNA expression (Figure 3).
DNA methylation was not significantly correlated with
relative total aromatase expression at sites I.4.1 (R = 0.302,
P = 0.142), I.4.2 (R = 0.047, P = 0.824) or I.4.4 (R = −0.063,
P = 0.774). Similarly a positive correlation was also seen
between DNA methylation and the I.4 promoter specific
relative gene expression (Figure 3). The correlation be-
tween the I.4.5 CpG site and PI.4 aromatase expression
remained significant after the exclusion of men (R = 0.473,
P = 0.047). There were no correlations between percentageFigure 3 Correlation between percentage DNA methylation at CpG si
(n = 25) and I.4 promoter transcript aromatase expression (n = 19) in
methylation percentage at the I.4.3 CpG site and total aromatase expressio
percentage at the I.4.5 CpG site and total aromatase expression (R = 0.549,
the I.4.3 CpG site and PI.4 aromatase expression (R = 0.449, P = 0.062). Botto
and PI.4 aromatase expression (R = 0.476, P = 0.040).DNA methylation of the I.4 promoter CpG sites and rela-
tive PI.3 transcript expression.Site specific methylation, gene expression and phenotype
Methylation levels at the 5 CpG sites were not associated
with age, weight or BMI in either tissue type. In subcuta-
neous adipocytes CpG methylation at the I.4.4 methylation
was significantly lower in males than females (21% vs.
39%), there were no other differences between males and
females at other sites. There was no difference in total or
I.4 promoter specific relative gene expression in either
depot. In 10 participants with whole body DXA (9 women
and 1 man) subcutaneous adipocytes I.4.5 methylation
percentage was correlated with increased headless whole
body bone mineral content (R = 0.783, P = 0.007), bone
mineral density (R = 0. 0.636, P = 0.048) and lean mass
(R = 0.661, P = 0.038), but not whole body bone area, lean
or fat mass (data not shown).tes 3 and 5 with total relative aromatase mRNA expression
human subcutaneous adipocytes. Top left: Correlation between
n in (R = 0.474, P = 0.022). Top right: Correlation between methylation
P = 0.004). Bottom left: Correlation between methylation percentage at
m right: Correlation between methylation percentage at the I.4.5 site
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In this study the correlation between DNA methylation
determined by pyrosequencing within the regulatory re-
gion of the I.4 promoter region and total aromatase gene
expression is extended to specific CpG sites from ex vivo
human subcutaneous and omental mature adipocytes.
The use of these primary fully differentiated cells allows
a “snapshot” of the actual tissue specific relationship be-
tween DNA methylation and gene expression. Specific-
ally we identified a negative correlation between DNA
methylation at 2 CpG sites (I.4.1 and I 4.2) upstream of
the aromatase promoter with aromatase mRNA expres-
sion in omental adipocytes. While in subcutaneous
adipocytes percentage DNA methylation at I.4.3 site up-
stream of the transcription start site (TSS) and the I.4.5
site downstream of the TSS within the transcribed
region of the gene were positively correlated with total
aromatase mRNA expression. This “snapshot” of the
DNA methylation status and gene expression in mature
adipocytes expressing aromatase extends upon the find-
ings of others using in vitro studies and supports the hy-
pothesis that DNA methylation may play a role in tissue
specific estrogen production.
Many epigenetic studies of DNA methylation and gene
expression focus on genes with large CpG islands span-
ning the promoter regions of transcriptional initiation
sites [38] and negative correlations between DNA
methylation of CpG islands in the region of promoters
and gene expression have been well described. However
“non-classical” mechanisms are poorly understood. Given
that the promoter regions of the aromatase gene does
not contain CpG islands and is relatively CpG poor in
comparison to other genomic regions [21,39-41] it is
unlikely that “classical” epigenetic regulation is occur-
ring at this site. An example of epigenetic regulation of
a CpG poor promoter is that of the cytochrome p450
27B1 (CYP27B1) gene promoter where 13 CpG sites
around the transcription start site are either hyper-
methylated by vitamin D binding to an upstream regula-
tory site or demethylated in the presence of parathyroid
hormone in MCTcells [42].
Two DNA methylation sites (I.4.1, I.4.2) that are 34 bp
upstream from the glucocorticoid response element were
negatively correlated with total aromatase gene expres-
sion in omental adipocytes. These findings are similar to
those reported by Knower et al. [11].
Unlike omental adipocytes a strong positive correl-
ation was observed between DNA methylation I.4.5 CpG
sites and a somewhat weaker correlation with the I.4.3
site and aromatase mRNA expression in subcutaneous
adipocytes. While DNA methylation within transcribed
regions has previously been correlated with increased
gene expression the mechanisms still remain uncertain
[18-20]. A number of other potential models that mayexplain the correlation between DNA methylation within
the transcribed gene regions and aromatase expression in
mature adipocytes exist, including regulation of alternative
promoter initiation [43], heterogeneity amongst the ma-
ture adipocyte population purified or splicing [44,45]
which is particularly likely given the tissue specific pro-
moter usage of the aromatase gene [6] and the proximity
of the I.4.5 CpG site to the splice junction. DNA methyla-
tion at the I.4.5 CpG site in subcutaneous adipocytes was
also significantly positively associated with bone and body
composition phenotypes. However caution must be taken
in interpreting these findings given the nature of the co-
hort and the small number of participants with whole
body composition and bone mineral density.
The strongest correlation between DNA methylation
similarly was observed at the intragenic I.4.5 site located
within a SP1 binding site that has previously been
demonstrated to be important regulatory site for gluco-
corticoid stimulated aromatase gene expression in pri-
mary fetal hepatocytes and adipose derived stromal cells
[9]. SP1 itself is an important regulator of CpG methyla-
tion status and when bound is thought to lead to
hypomethylation enhanced transcription [46]. Interest-
ingly, DNA methylation within the SP1 binding site does
not appear to block SP1 binding [47], however it may be
possible that DNA methylation within the SP1 binding
site may block transcriptional repressors such as R1
(RAM2/CDCA7L/JPO2) or E2F-associated phosphopro-
tein (EAPP) that compete with SP1 to bind to the SP1
binding site and have been reported to repress gluco-
corticoid dependant activation in other genes [48] fur-
ther supporting the findings of others that adipocytes
from subcutaneous tissue have greater responsiveness to
glucocorticoids than omental tissue-derived adipocytes
[23]. However further studies are needed to confirm the
mechanism influencing these findings and its physio-
logical role in estrogen production.
The strengths of this study was the use of matched
omental and subcutaneous adipocytes, a purified homo-
genous ex vivo cell type to determine the relationship of
DNA methylation within the I.4 promoter region with
aromatase expression from a large number of human
ex vivo samples not exposed to environmental hypo-
methylating agents in cell culture or extended passages.
This model is therefore likely to represent endogenous
relationships in mature adipocytes which are the primary
extra-glandular source of estrogen in both men and
women. The study also used pyrosequencing which is
considered the “gold standard” for determining DNA
methylation, in particular the inbuilt quality controls
for bisulfite treatment [49] gives highly reproducible
results [50] thus enabling quantitation of DNA methy-
lation percentage at several CpG sites within close
proximity [36].
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nature however as yet no method of altering site specific
DNA methylation status exists in primary human cells
and hypo-methylation agents such as 5-aza-dC do not
appear to hypomethylate CpG sites within the I.4 region
of the aromatase gene in vitro [11]. Therefore currently
the technology is not available to determine whether site
specific DNA methylation actually alters gene expression
in these cells.
Conclusions
These data demonstrate that DNA methylation of spe-
cific CpG sites across the I.4 promoter region is variable
exhibiting both positive and negative correlations with
aromatase expression in mature ex vivo adipocytes de-
pending on the tissue depot. In addition DNA methyla-
tion at one CpG site within the transcribed region in
subcutaneous adipocytes was correlated with body com-
position and bone mineral density as well as gene ex-
pression. These data further support the concept that
epigenetic mechanisms may be involved in the regula-
tion of aromatase expression and may be important in
the determination of body composition by mechanisms
yet to be identified.
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